Cardoso Ana-Carolina, de Figueiredo-Mendes Claudio, A Villela-Nogueira Cristiane, Sanyal Arun J
Hepatology Division, Clementino Fraga Filho University Hospital, Rio de Janeiro, Brazil.
School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Liver Int. 2020 Feb;40 Suppl 1:96-101. doi: 10.1111/liv.14354.
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in Western countries. At present the safest and most effective first-line therapy for the management of non-alcoholic steatohepatitis (NASH) is lifestyle modification with diet and exercise. However, long-term adherence to lifestyle modification is rare in the target population, leading to progression of liver disease and its complications such as cirrhosis and hepatocellular carcinoma. Thus, new drugs that focus mainly on the pathogenesis of NASH to target inflammation and fibrogenesis are under investigation. This mini-review summarizes the results of pivotal finalized phase 2 studies, and provide an outline of ongoing phase 2 and phase 3 studies.
非酒精性脂肪性肝病（NAFLD）是西方国家慢性肝病的主要病因。目前，用于管理非酒精性脂肪性肝炎（NASH）最安全、最有效的一线治疗方法是通过饮食和运动进行生活方式调整。然而，目标人群中很少有人能长期坚持生活方式调整，这导致了肝病进展及其诸如肝硬化和肝细胞癌等并发症。因此，主要针对NASH发病机制以靶向炎症和纤维化形成的新药正在研究中。本综述总结了关键的已完成2期研究结果，并概述了正在进行的2期和3期研究。
